Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: Results from the IBIS-II, chemoprevention study using anastrozole

Breast Cancer Research and Treatment

Volumn 132, Issue 2, 2012, Pages 625-629

  Singh, Shalini ^a   Cuzick, Jack ^a   Mesher, David ^a   Richmond, Bill ^b   Howell, Anthony ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aromatase inhibitors; Arthralgia; Breast cancer; Vitamin D

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; GLUCOSAMINE; MULTIVITAMIN; PARACETAMOL; PLACEBO; VITAMIN D;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL; VITAMIN D BLOOD LEVEL;

ADULT; AGED; ANTICARCINOGENIC AGENTS; AROMATASE INHIBITORS; ARTHRALGIA; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NITRILES; ODDS RATIO; PLACEBOS; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TRIAZOLES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84859023636     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1911-6     Document Type: Article

References (36)

1. Pfeifer M, Begerow B, Minne HW (2002) Vitamin Dand muscle function. Osteoporos Int 13(3):187-194
2. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB et al. (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. Br Med J 339:b3692
3. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC et al. (2004) Effect of Vitamin Don falls: a meta-analysis. JAMA 291(16):1999-2006 (Pubitemid 38544282)
4. Waltman NL, Ott CD, Twiss JJ, Gross GJ, Lindsey AM (2009) Vitamin Dinsufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy. Cancer Nurs 32(2):143-150
5. Waltman NL, Ott CD, Twiss JJ et al. (2008) Bone mineral density and bone turnover in postmenopausal women treated for breast cancer. Cancer Nurs 31(3):182-190 (Pubitemid 351652216)
6. Croft P, Rigby AS, Boswell R, Schollum J, Silman A (1993) The prevalence of chronic widespread pain in the general population. J Rheumatol 20(4):710-713 (Pubitemid 23138864)
7. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38(1):19-28
8. Goss PE (2003) Breast cancer prevention-clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 86(3-5):487-493
9. Coombes RC, Hall E, Gibson LJ et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081-1092 (Pubitemid 38298988)
10. Coombes RC, Kilburn LS, Snowdon CF et al. (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years'tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559-570
11. Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52(9):2594-2598 (Pubitemid 41369086)
12. Howell A, Cuzick J, Baum M et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453):60-62
13. Jakesz R, Jonat W, Gnant M et al. (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455-462 (Pubitemid 41111693)
14. Thurlimann B, Keshaviah A, Coates AS et al. (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747-2757 (Pubitemid 43016814)
15. Burstein HJ, Winer EP (2007) Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 25(25):3797-3799 (Pubitemid 47477251)
16. Crew KD, Greenlee H, Capodice J et al. (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877-3883 (Pubitemid 47477264)
17. Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. (2009) Letrozole therapy alone orin sequence with tamoxifen in women with breast cancer. N Engl J Med 361(8):766-776
18. Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107(2):167-180 (Pubitemid 350265697)
19. Donnellan PP, Douglas SL, Cameron DA, Leonard RC (2001) Aromatase inhibitors and arthralgia. J Clin Oncol 19(10):2767
20. Holick MF (2006) The role of vitamin D for bone health and fracture prevention. Curr Osteoporos Rep 4(3):96-102
21. Heaney RP (2005) The Vitamin Drequirement in health and disease. J Steroid Biochem Mol Biol 97(1-2):13-19
22. Holick MF, Siris ES, Binkley N et al. (2005) Prevalence of Vitamin Dinadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90(6):3215-3224 (Pubitemid 41014278)
23. Plotnikoff GA, Quigley JM (2003) Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 78(12):1463-1470 (Pubitemid 37475629)
24. Malabanan A, Veronikis IE, Holick MF (1998) Redefining vitamin Dinsufficiency. Lancet 351(9105):805-806
25. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ (2003) Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77(1):204-210 (Pubitemid 36015393)
26. Prieto-Alhambra D, Javaid MK, Servitja S et al. (2010) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia:a prospective cohort study. Breast Cancer Res Treat
27. Khan QJ, Reddy PS, Kimler BF et al. (2009) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat
28. Taylor M, Rastelli A, Civitelli R, Ellis M (2004) Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. 27th San-Antonio Breast Cancer Symposium, San-Antonio
29. Hollis BW, Napoli JL (1985) Improved radioimmunoassay for vitamin D and its use in assessing vitamin D status. Clin Chem 31(11):1815-1819 (Pubitemid 16012541)
30. Warner AE, Arnspiger SA (2008) Diffuse musculoskeletal pain isnot associated with low vitamin D levels or improved by treatment with vitamin D. J Clin Rheumatol 14(1):12-16
31. Fontaine C, Meulemans A, Huizing M et al. (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast 17(4):376-381
32. Partridge AH, LaFountain A, Mayer E et al. (2008) Adherence toinitial adjuvant anastrozole therapy among women with earlystage breast cancer. J Clin Oncol 26(4):556-562 (Pubitemid 351264348)
33. Block SR (2004) Vitamin D deficiency is not associated with nonspecific musculoskeletal pain syndromes including fibromyalgia. Mayo Clin Proc 79(12):1585-1586 author reply 1586-7
34. Sanders KM, Stuart AL, Williamson EJ et al. (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303(18):1815-1822
35. Utiger RD (1998) The need for more vitamin D. N Engl J Med 338(12):828-829
36. Aguado P, Del Campo MT, Garces MV et al. (2000) Low vitamin Dlevels in outpatient postmenopausal women from a rheumatology clinic in Madrid, Spain: their relationship with bone mineral density. Osteoporos Int 11(9):739-744